This is one of the most frequently asked, least straightforwardly answered questions we get. The honest starting point: dedicated human safety data during lactation is essentially absent for nearly every peptide discussed on this site, research-use or otherwise.
Why the Data Gap Exists
Lactating individuals are routinely excluded from clinical trials for ethical and practical reasons, which means the absence of documented harm for a given compound is not the same thing as documented safety. This data gap applies broadly across the peptide research space, not to any single compound.
The Default, Conservative Position
Given that gap, the responsible default is to treat research-use peptides as not established safe during breastfeeding and to avoid them unless a prescribing physician who knows your full medical picture has specifically evaluated a particular compound and determined the benefit outweighs an unknown risk.
Compounds That Warrant Extra Caution
GLP-1 agonists, growth-hormone secretagogues, and any compound with systemic hormonal activity are worth flagging specifically to a lactation consultant or physician, given their mechanism of action overlaps with pathways relevant to milk supply and infant development. This is not a claim that they cause harm — it’s a reflection of how little is specifically known.
Who to Actually Talk To
An IBCLC (International Board Certified Lactation Consultant) working alongside your OB or primary care provider is the right team for this decision — not a research-vendor FAQ page, including this one.